Literature DB >> 8624871

DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience.

A K Slade1, N Sadoul, L Shapiro, L Chojnowska, J P Simon, R C Saumarez, B Dodinot, A J Camm, W J McKenna, E Aliot.   

Abstract

BACKGROUND: DDD pacing has been advocated as an effective treatment for drug refractory obstructive hypertrophic cardiomyopathy. This study reports the outcome of pacing in 56 patients with refractory symptoms referred to four tertiary centres.
METHODS: Core data on symptoms, drug burden, and left ventricular outflow tract gradient were recorded. Patients underwent a temporary pacing study with optimisation of the atrioventricular (AV) delay for greatest gradient reduction without haemodynamic compromise. Patients were assessed after implantation in terms of changes in symptoms, drug load, and outflow tract gradient.
RESULTS: 56 patients underwent pacing assessment. The mean (SD) left ventricular outflow tract gradient before pacing was 78 (31) mm Hg. At temporary study the mean (SD) left ventricular outflow tract gradient was 38 (24) mm Hg with a median (range) optimised sensed AV delay of 65 (25-125) ms. Fifty three patients were implanted and followed up for a mean (SD) of 11 (11) months. The median (range) programmed sensed AV delay was 60 (31-200) ms. Left ventricular outflow tract gradient at follow up was 36 (25) mm Hg. Forty four patients had improved functional class. Although a correlation (r = 0.69) was shown between acute and chronic left ventricular outflow tract gradient reduction, there was no correlation between magnitude of gradient reduction and functional improvement, and no appreciable change in pharmacological burden.
CONCLUSION: This series confirms symptomatic improvement after DDD pacing in hypertrophic cardiomyopathy. There remains, however, a discrepancy between perceived symptomatic benefit and modest objective improvement. Furthermore, the optimal outcome has been achieved only with continued pharmacological treatment. Current methods of temporary evaluation do not predict functional outcome which seems to be independent of the magnitude of gradient reduction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624871      PMCID: PMC484221          DOI: 10.1136/hrt.75.1.44

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  23 in total

1.  Current operative treatment of obstructive hypertrophic cardiomyopathy.

Authors:  C L McIntosh; B J Maron
Journal:  Circulation       Date:  1988-09       Impact factor: 29.690

2.  Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years.

Authors:  H D Schulte; W H Bircks; B Loesse; E A Godehardt; B Schwartzkopff
Journal:  J Thorac Cardiovasc Surg       Date:  1993-10       Impact factor: 5.209

3.  Dual chamber pacing for hypertrophic obstructive cardiomyopathy: has its time come?

Authors:  R A Nishimura; G K Danielson
Journal:  Br Heart J       Date:  1993-10

4.  The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy. Experience over 15 years.

Authors:  R Mohr; H V Schaff; G K Danielson; F J Puga; J R Pluth; A J Tajik
Journal:  J Thorac Cardiovasc Surg       Date:  1989-05       Impact factor: 5.209

5.  Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy.

Authors:  L Fananapazir; R O Cannon; D Tripodi; J A Panza
Journal:  Circulation       Date:  1992-06       Impact factor: 29.690

6.  Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT).

Authors:  J Rawles
Journal:  J Am Coll Cardiol       Date:  1994-01       Impact factor: 24.094

7.  Importance of left atrial timing in the programming of dual-chamber pacemakers.

Authors:  M Wish; R D Fletcher; J S Gottdiener; A I Cohen
Journal:  Am J Cardiol       Date:  1987-09-01       Impact factor: 2.778

8.  Differing effects of right ventricular pacing and left bundle branch block on left ventricular function.

Authors:  H B Xiao; S J Brecker; D G Gibson
Journal:  Br Heart J       Date:  1993-02

9.  Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy.

Authors:  X Jeanrenaud; J J Goy; L Kappenberger
Journal:  Lancet       Date:  1992-05-30       Impact factor: 79.321

10.  The hemodynamic benefit of differential atrioventricular delay intervals for sensed and paced atrial events during physiologic pacing.

Authors:  D L Janosik; A C Pearson; T A Buckingham; A J Labovitz; R M Redd
Journal:  J Am Coll Cardiol       Date:  1989-08       Impact factor: 24.094

View more
  14 in total

Review 1.  Analysis of dual-chamber pacing as a treatment for refractory limiting symptoms in patients with obstructive hypertrophic cardiomyopathy.

Authors:  B J Maron
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  [Mitral valve replacement for three cases of hypertrophic obstructive cardiomyopathy--surgical treatment].

Authors:  Y Koh; T Okubo; R Hoshino; Y Kamigaki; S Ouchi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-08

4.  eComment. Septal reduction therapy for hypertrophic cardiomyopathy: the need of experienced centres.

Authors:  Ovidio A Garcia-Villarreal
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01

5.  Effect of alcohol septal ablation in patients with hypertrophic cardiomyopathy on left-ventricular mechanical dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging.

Authors:  Ji Chen; Hosakote Nagaraj; Pradeep Bhambhani; Dustin E Kliner; Prem Soman; Ernest V Garcia; Jaekyeong Heo; Ami E Iskandrian
Journal:  Int J Cardiovasc Imaging       Date:  2011-08-24       Impact factor: 2.357

Review 6.  Mechanisms and efficacy of LV pre-excitation for patients with heart failure and supra-normal systolic function.

Authors:  D A Kass
Journal:  Heart Fail Rev       Date:  2000-12       Impact factor: 4.214

Review 7.  Dual-chamber pacing in hypertrophic cardiomyopathy.

Authors:  D M Gilligan
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

8.  Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients.

Authors:  Antonio Berruezo; Markus Linhart; Angelo Auricchio; José Luis Zamorano; Pilar Santamaria; Roger Borràs; Felip Burgos; Josep Brugada
Journal:  J Interv Card Electrophysiol       Date:  2018-02-03       Impact factor: 1.900

9.  Therapeutic options in hypertrophic cardiomyopathy: a pediatric perspective.

Authors:  Edward K Rhee; John J Nigro; Stephen G Pophal
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

Review 10.  Update on hypertrophic cardiomyopathy and a guide to the guidelines.

Authors:  Srijita Sen-Chowdhry; Daniel Jacoby; James C Moon; William J McKenna
Journal:  Nat Rev Cardiol       Date:  2016-09-29       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.